Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Exchange Rate Effect (2020 - 2022)

Xeris Biopharma Holdings (XERS) has disclosed Exchange Rate Effect for 3 consecutive years, with $1000.0 as the latest value for Q3 2022.

  • For the quarter ending Q3 2022, Exchange Rate Effect rose 150.0% year-over-year to $1000.0, compared with a TTM value of $1000.0 through Jun 2023, up 120.0%, and an annual FY2021 reading of -$3000.0, up 86.36% over the prior year.
  • Exchange Rate Effect was $1000.0 for Q3 2022 at Xeris Biopharma Holdings, up from -$1000.0 in the prior quarter.
  • Across five years, Exchange Rate Effect topped out at $6000.0 in Q4 2020 and bottomed at -$2000.0 in Q3 2021.
  • Average Exchange Rate Effect over 3 years is $500.0, with a median of $0.0 recorded in 2021.
  • The sharpest move saw Exchange Rate Effect crashed 133.33% in 2021, then skyrocketed 150.0% in 2022.
  • Year by year, Exchange Rate Effect stood at $6000.0 in 2020, then crashed by 133.33% to -$2000.0 in 2021, then surged by 150.0% to $1000.0 in 2022.
  • Business Quant data shows Exchange Rate Effect for XERS at $1000.0 in Q3 2022, -$1000.0 in Q1 2022, and -$2000.0 in Q4 2021.